Investors

Euronext Amsterdam: DSFIR

We're dsm-firmenich - innovators in nutrition, health, and beauty

As a high-value consumer ingredients leader, we’re making rapid progress on our strategic journey to resilient growth

Latest results - H1 2026

H1 2026 highlights

  • Good like-for-like (LFL) sales growth of 5% in H1 2026, with 6% in Q2
  • Adjusted EBITDA margin improved sequentially, with positive momentum into second half
  • Continued improvement in adjusted gross operating free cash flow
  • 2026-2028 action plan, aimed at accelerating financial performance, introduced at March 2026 CMD, fully on track
  • Successful dual listing of shares on SIX Swiss Exchange as of May 21
  • €500 million share buyback program progressing well
  • Outlook unchanged: 2026 targets underpinned by good H1 delivery 

Why invest in dsm-firmenich

dsm-firmenich are innovators in nutrition, health, and beauty, bringing progress to life through solving the tension between what people individually want (the desirable), what we collectively need (the essential) and what the planet demands (the sustainable).

We are strategically placed to capitalise on the positive long-term mega trend of holistic well-being which is fuelling above-market growth opportunities in our three, synergistic BUs operating in nutrition, health, and beauty creating and innovating in an integrated way.

Demand for fragrances and beauty products has surged, with scent being a key purchase driver

 

Consumers are prioritizing healthy nutrition 

 

The share of spend on preventative health is increasing year on year 

 

Our purpose

We have deep roots and a bright future, with unrivaled expertise that drives positive impact in everything we do. Our purpose is to bring progress to life – creating a world of potential for customers, communities, consumers, and investors.

Latest news

  • dsm-firmenich Board of Directors proposes Richard Ridinger as new Chairman following Thomas Leysen’s decision to retire

    18 August 2026

    dsm-firmenich Board of Directors proposes Richard Ridinger as new Chairman following Thomas Leysen’s decision to retire

  • dsm-firmenich reports H1 2026 results

    30 July 2026

    dsm-firmenich reports H1 2026 results

  • dsm firmenich unveils Flowers Are Watching Us, a new global activation presenting a fresh take on florals in perfumery

    6 July 2026

    dsm firmenich unveils Flowers Are Watching Us, a new global activation presenting a fresh take on florals in perfumery

Contact Investor Relations

Whether you’re a shareholder, potential shareholder, or analyst, our Investor relations team is on hand to answer your questions.

Explore more
  • dsm-firmenich at a glance

    Who we are. What we do. Where we’re going.

  • Analyst coverage & consensus

    The sell-side analysts covering dsm-firmenich and latest Vara consensus figures.

  • Financial calendar

    A handy overview of the key dates in our financial calendar.

Stay up to date

Be the first to know about key news as we continue shaping the future and bringing progress to life.